Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 16,300 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) insider David Raben sold 16,300 shares of Bicara Therapeutics stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total transaction of $301,876.00. Following the completion of the sale, the insider directly owned 55,286 shares in the company, valued at approximately $1,023,896.72. This represents a 22.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

David Raben also recently made the following trade(s):

• On Tuesday, March 3rd, David Raben sold 200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.45, for a total transaction of $3,690.00.

Bicara Therapeutics Price Performance

Bicara Therapeutics stock traded down $0.04 during trading on Thursday, hitting $18.50. The stock had a trading volume of 950,200 shares, compared to its average volume of 516,872. The stock’s 50 day moving average is $16.43 and its two-hundred day moving average is $15.70. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $19.71.

Hedge Funds Weigh In On Bicara Therapeutics

Large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $45,000. Legal & General Group Plc lifted its position in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares during the period. Larson Financial Group LLC grew its position in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the period.

Wall Street Analyst Weigh In

BCAX has been the topic of a number of research reports. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Citigroup started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Finally, Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $28.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.